Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Thalia Therap. (THAT) Share Price

Price 0.70p on 23-07-2026 at 17:45:10
Change 0.00p 0%
Buy 0.75p
Sell 0.65p
Last Trade: Sell 4,134.00 at 0.65p
Day's Volume: 3,909,372
Last Close: 0.70p
Open: 0.70p
ISIN: GB00BYW8QM32
Day's Range 0.70p - 0.70p
52wk Range: 0.375p - 0.90p
Market Capitalisation: £8.46m
VWAP: 0.688776p
Shares in Issue: 1.21b

Thalia Therap. (THAT) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 4,134 0.65p SI Trade
13:52:24 - 23-Jul-26
Buy* 1,234 0.75p SI Trade
12:35:52 - 23-Jul-26
Buy* 2,101 0.75p SI Trade
11:35:48 - 23-Jul-26
Buy* 106 0.75p SI Trade
11:35:48 - 23-Jul-26
Sell* 1,816 0.65p SI Trade
11:35:48 - 23-Jul-26
Buy* 6,454 0.75p SI Trade
11:35:48 - 23-Jul-26
Sell* 6,033 0.65p SI Trade
11:35:48 - 23-Jul-26
Buy* 933 0.75p SI Trade
11:35:48 - 23-Jul-26
Unknown* 1,145,039 0.655p Ordinary
10:04:05 - 23-Jul-26
Sell* 735,295 0.68p Ordinary
10:02:10 - 23-Jul-26
See more Thalia Therap. trades

Thalia Therap. (THAT) Share Price History

Time period:
to
Date Open High Low Close Volume
23rd Jul 2026 (Thu) 0.70 0.70 0.70 0.70 3,909,372
22nd Jul 2026 (Wed) 0.65 0.70 0.65 0.70 3,165,671
21st Jul 2026 (Tue) 0.65 0.65 0.65 0.65 1,516,729
20th Jul 2026 (Mon) 0.65 0.65 0.65 0.65 313,251
17th Jul 2026 (Fri) 0.65 0.65 0.65 0.65 10,484,667
16th Jul 2026 (Thu) 0.65 0.65 0.65 0.65 868,813
15th Jul 2026 (Wed) 0.65 0.65 0.65 0.65 865,580
14th Jul 2026 (Tue) 0.65 0.65 0.65 0.65 340,962
13th Jul 2026 (Mon) 0.65 0.65 0.65 0.65 757,212
10th Jul 2026 (Fri) 0.65 0.65 0.65 0.65 132,766
9th Jul 2026 (Thu) 0.65 0.65 0.65 0.65 4,632
8th Jul 2026 (Wed) 0.65 0.65 0.65 0.65 56,884
7th Jul 2026 (Tue) 0.65 0.65 0.65 0.65 404,350
6th Jul 2026 (Mon) 0.65 0.65 0.65 0.65 166,009
3rd Jul 2026 (Fri) 0.65 0.65 0.65 0.65 540,650
2nd Jul 2026 (Thu) 0.65 0.65 0.65 0.65 101,628
1st Jul 2026 (Wed) 0.65 0.65 0.65 0.65 9,735,127
30th Jun 2026 (Tue) 0.65 0.65 0.65 0.65 215,510
29th Jun 2026 (Mon) 0.65 0.65 0.65 0.65 12,281
26th Jun 2026 (Fri) 0.65 0.65 0.65 0.65 3,354,642
25th Jun 2026 (Thu) 0.675 0.675 0.65 0.65 5,108,118
24th Jun 2026 (Wed) 0.625 0.675 0.625 0.675 11,671,501
See more Thalia Therap. price history

Thalia Therap. (THAT) Regulatory News

Date Source Headline
23rd Jul 2026 9:25 am RNS Grant of Director Share Options
21st Jul 2026 5:23 pm RNS Holding(s) in Company
21st Jul 2026 5:21 pm RNS Holding(s) in Company
21st Jul 2026 11:36 am RNS Holding(s) in Company
17th Jul 2026 11:21 am RNS Result of AGM and Completion of Acquisition
17th Jul 2026 7:00 am RNS AGM Statement
24th Jun 2026 3:21 pm RNS Posting of Annual Report and Notice of AGM
24th Jun 2026 7:00 am RNS Acquisition and £2.75 million Fundraise
23rd Jun 2026 5:04 pm RNS Final Results
9th Jun 2026 7:00 am RNS-R New article: RNA medicine enters its second act
See more Thalia Therap. regulatory news

Thalia Therap. (THAT) Share News

UK shareholder meetings calendar - next 7 days

10th Jul 2026 13:43

Read More

TRADING UPDATES: Tullow Oil makes partial notes repayment

24th Jun 2026 13:40

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More

LONDON MARKET MIDDAY: Stocks mixed but no "contagion" from US sell-off

24th Jun 2026 11:59

(Alliance News) - The FTSE 100 was higher at midday on Wednesday, boosted by Segro after it rejected an "opportunistically timed" takeover proposal, and as the US and Iran reportedly prepare to restart 'technical talks'. Read More

IN BRIEF: Thalia Therapeutics eyes adding microRNA therapeutic asset

23rd Jun 2026 20:20

Thalia Therapeutics PLC - biotechnology company developing innovative RNA therapeutics - Pretax loss is flat at GBP1.2 million in 2025 when compared to the year prior. Loss per share is 0.17 pence versus 0.31p the year before, revenue is little changed at GBP7,264 versus GBP7,282. Research and development costs fall to GBP214,120 from GBP390,387 and general and administration costs rise to GBP1.0 million from GBP837,996. "Alongside our internally developed assets, we are in advanced stages of potentially adding a clinical-stage microRNA therapeutic asset to the company's portfolio. If successful, this, combined with the continued advancement of Nuvec, our dual-targeting siRNA programme, is the first step in creating a differentiated and valuable RNA therapeutics company," says Chief Executive David Solomon. Read More

EARNINGS AND TRADING: Asia Strategic Holdings revenue declines

9th Jun 2026 18:19

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More

See more Thalia Therap. news
FTSE 100 Latest
Value10,639.17
Change-77.80

Login to your account

Forgot Password?

Not Registered